Buy or sell Gliknik stock pre IPO via an EquityZen fund
Gliknik develops therapies for patients with cancer and immune disorders.
About Gliknik Stock
Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the efficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to monocolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
Founder, President and CEO
David S. Block
Founder & Scientist
Scott E. Strome